Bionomics (BNOX)
(Delayed Data from NSDQ)
$1.01 USD
+0.01 (1.00%)
Updated Apr 29, 2024 03:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Bionomics Limited Unsponsored ADR falls in the month of June.
All items in Millions except Per Share data.
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 12 | 24 | 22 | -99,999 | -99,999 |
Receivables | 0 | 5 | 1 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 1 | 1 | 1 | NA | NA |
Total Current Assets | 14 | 30 | 23 | NA | NA |
Net Property & Equipment | 0 | 0 | 0 | NA | NA |
Investments & Advances | 0 | 0 | 0 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 15 | 16 | 17 | NA | NA |
Deposits & Other Assets | 0 | 0 | 0 | NA | NA |
Total Assets | 29 | 47 | 41 | NA | NA |
Liabilities & Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | NA |
Accounts Payable | 2 | 2 | 1 | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 0 | 0 | 0 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 0 | 0 | 0 | NA | NA |
Total Current Liabilities | 3 | 2 | 2 | NA | NA |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 1 | 1 | 1 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 1 | NA | NA |
Other Non-Current Liabilities | 3 | 2 | 1 | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 7 | 6 | 5 | NA | NA |
Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | NA |
Common Stock (Par) | 150 | 158 | 142 | NA | NA |
Capital Surplus | 0 | 0 | 0 | NA | NA |
Retained Earnings | -138 | -126 | -115 | NA | NA |
Other Equity | 10 | 9 | 9 | NA | NA |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 22 | 41 | 36 | NA | NA |
Total Liabilities & Shareholder's Equity | 29 | 47 | 41 | NA | NA |
Total Common Equity | 22 | 41 | 36 | 0 | 0 |
Shares Outstanding | 8.10 | 5.60 | 5.60 | NA | NA |
Book Value Per Share | 2.76 | 7.37 | 6.35 | 0.00 | 0.00 |
Fiscal Year End for Bionomics Limited Unsponsored ADR falls in the month of June.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,989 | -99,999 | 12 | -99,999 |
Receivables | NA | 0 | NA | 0 | NA |
Notes Receivable | NA | NA | NA | 0 | NA |
Inventories | NA | NA | NA | 0 | NA |
Other Current Assets | NA | 1 | NA | 1 | NA |
Total Current Assets | NA | 11 | NA | 14 | NA |
Net Property & Equipment | NA | 0 | NA | 0 | NA |
Investments & Advances | NA | 0 | NA | 0 | NA |
Other Non-Current Assets | NA | NA | NA | 0 | NA |
Deferred Charges | NA | NA | NA | 0 | NA |
Intangibles | NA | 14 | NA | 15 | NA |
Deposits & Other Assets | NA | NA | NA | 0 | NA |
Total Assets | NA | 25 | NA | 29 | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | NA |
Accounts Payable | NA | 2 | NA | 2 | NA |
Current Portion Long-Term Debt | NA | 1 | NA | 0 | NA |
Current Portion Capital Leases | NA | 0 | NA | 0 | NA |
Accrued Expenses | NA | NA | NA | 0 | NA |
Income Taxes Payable | NA | NA | NA | 0 | NA |
Other Current Liabilities | NA | 0 | NA | 0 | NA |
Total Current Liabilities | NA | 3 | NA | 3 | NA |
Mortgages | NA | NA | NA | 0 | NA |
Deferred Taxes/Income | NA | 1 | NA | 1 | NA |
Convertible Debt | NA | NA | NA | 0 | NA |
Long-Term Debt | NA | NA | NA | 0 | NA |
Non-Current Capital Leases | NA | 0 | NA | 0 | NA |
Other Non-Current Liabilities | NA | NA | 3 | NA | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | NA |
Total Liabilities | NA | 6 | NA | 7 | NA |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | NA |
Common Stock (Par) | NA | 152 | NA | 150 | NA |
Capital Surplus | NA | NA | NA | 0 | NA |
Retained Earnings | NA | -142 | NA | -138 | NA |
Other Equity | NA | 9 | NA | 10 | NA |
Treasury Stock | NA | NA | NA | 0 | NA |
Total Shareholder's Equity | NA | 19 | NA | 22 | NA |
Total Liabilities & Shareholder's Equity | NA | 25 | NA | 29 | NA |
Total Common Equity | 0 | 100,018 | 0 | 22 | 0 |
Shares Outstanding | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 |
Book Value Per Share | 0.00 | 12,347.89 | 0.00 | 2.76 | 0.00 |